The lawsuit alleges civil violations of the Racketeer Influenced and Corrupt Organizations Act, or RICO, the Connecticut ...

Insulin Market to exceed US$ 31.5 Bn by 2035, expanding at 4.1% CAGR, driven by rising diabetes prevalence and growing access to advanced ...

American tennis legend Serena Williams revealed taking the help of GLP-1 drugs to attain an ideal figure after struggling to ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Here are some of the stories Wall Street is watching on Friday, Aug. 22. Stocks and cryptocurrencies surged after Fed Chair ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...